iBio
IBIO
85 hedge funds and large institutions have $47.6M invested in iBio in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 22 increasing their positions, 19 reducing their positions, and 13 closing their positions.
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
16% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 19
2% more funds holding
Funds holding: 83 → 85 (+2)
0% more ownership
Funds ownership: 0.04% → 0.04% (+0%)
27% less capital invested
Capital invested by funds: $65.5M → $47.6M (-$17.9M)
48% less call options, than puts
Call options by funds: $1.02M | Put options by funds: $1.97M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$921K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$658K |
| 3 |
VF
Virtu Financial
New York
|
+$225K |
| 4 |
Renaissance Technologies
New York
|
+$189K |
| 5 |
Goldman Sachs
New York
|
+$182K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$326K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$257K |
| 3 |
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
|
-$225K |
| 4 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
-$178K |
| 5 |
Squarepoint
New York
|
-$162K |
IBIO Hedge Fund Activity: Q3 2021 in Review
85 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q3 2021, worth a combined $47.6M — down 27% from $65.5M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new IBIO positions and 13 closed out — a net gain of 3 holders — while 22 added to existing stakes and 19 trimmed.
The largest buyer was State Street, adding an estimated $921K. The largest seller was Susquehanna International Group, cutting an estimated $326K.
- 85 institutional investors held iBio (IBIO) as of Q3 2021, up from 83 in Q2 2021.
- Funds reported $47.6M of iBio stock for Q3 2021, down 27% quarter-over-quarter.
- 16 funds opened new iBio positions in Q3 2021 and 13 closed out, a net change of +3 holders.
- The largest iBio buyer in Q3 2021 was State Street, an estimated $921K added.
- The largest iBio seller in Q3 2021 was Susquehanna International Group, an estimated $326K sold.
Based on aggregated 13F filings for Q3 2021.